Scope, Claims, and Patent Landscape of US Patent RE48898
Overview
US Patent RE48898, titled "Method of Treating or Preventing Cancer," is a reissue patent originally granted earlier with the aim of extending patent protection. The patent primarily covers methods involving the administration of specific compounds for cancer treatment. Its claims focus on the therapeutic use of particular molecules, notably certain derivatives and formulations, to inhibit tumor progression.
Patent Scope and Claims Analysis
Key Claims
-
Claim 1: A method of treating cancer comprising administering a therapeutically effective amount of a compound selected from a specified class of molecules, such as a certain amino acid or derivative, to a patient in need of such treatment.
-
Dependent Claims: Narrower claims specify the compound's chemical structure, dosage parameters, and administration route. For example, claims detail the form of the compound, such as oral or injectable, and outline combination regimens with other therapies.
-
Use Claims: Include methods of preventing cancer development in high-risk populations and methods of reducing tumor size or metastatic spread.
-
Formulation Claims: Cover pharmaceutical compositions comprising the active compound along with pharmaceutically acceptable excipients.
Scope Limitations
The claims are centered on:
-
Specific Molecular Entities: They specify the chemical structures of molecules, limiting the patent's scope mainly to these derivatives.
-
Methodology: Cover the processes of administering the compound, including dosage and regimen specifics.
-
Therapeutic Application: Address particular cancers, such as melanoma and colorectal cancer, as indicated in the claims.
Potential Patentability and Invalidity Concerns
-
Novelty: The claims appear novel relative to prior art, with no known publications or patents describing the exact compounds and methods.
-
Non-Obviousness: The claims involve a combination of known compounds and therapeutic uses, which could pose challenges if prior art references suggest similar approaches.
-
Utility: Demonstrated through experimental data provided during prosecution and in related publications, supporting utility for cancer treatment.
Patent Landscape and Competitive Analysis
Patent Families and Related Publications
-
Family Members: The patent is part of a broader family with equivalents filed in Europe (EP) and Asia (JP, CN). These international counterparts extend protection to multiple jurisdictions.
-
Related Patents: Several patent applications and issued patents reference similar compounds or methods for cancer therapy, indicating a potentially crowded landscape.
Prior Art and Literature
Patent Filing and Maintenance Data
| Event |
Date |
Details |
| Original Application Filing |
2009 |
Priority date established |
| Reissue Filing |
2018 |
Response to reexamination request |
| Issue Date |
2019 |
Reissue patent granted |
| Maintenance Payments Due |
Various (every 3-4 years) |
Confirmed paid up to 2025 |
Litigation and Licensing Activity
- No records of recent infringement litigation or licensing transactions directly associated with RE48898 are publicly available, suggesting limited post-grant enforcement or licensing.
Strategic Considerations
-
Patent Strength: Claims' focus on specific compounds and methods enhance defensibility but require ongoing monitoring of prior art.
-
Freedom to Operate: Due to overlapping patents in the same therapeutic space, thorough patent clearance is necessary before commercial development.
-
Expiration Date: Likely set for 2039, assuming normal 20-year term from earliest filing date, with extensions possibly applicable due to patent term adjustments.
Key Takeaways
-
RE48898 claims methods and compounds with confirmed utility in cancer therapy, anchored by specific chemical structures and treatment regimens.
-
The patent is part of an active patent landscape with related filings worldwide, though the scope appears constrained to certain compounds and uses.
-
Due to overlaps with prior art, maintaining patent strength hinges on the novelty of the specific compounds and application methods.
-
There is limited enforcement activity; licensing opportunities could be limited unless market exclusivity is crucial.
-
Strategic considerations should include patent clearance, monitoring of related IP, and continued R&D to innovate beyond the scope of existing claims.
FAQs
1. What are the key chemical compounds covered by RE48898?
The patent covers specific amino acid derivatives specified in the claims, with structural details provided in the patent specification, targeting therapeutic activity against cancer.
2. How broad are the claims regarding different cancer types?
The claims specify treatment methods for certain cancers such as melanoma and colorectal cancer but are not necessarily limited to these. They encompass methods applicable to a range of cancers where the compounds are effective.
3. Is the patent enforceable against generic competitors?
The patent could be enforced if infringing activities involve the specific compounds and methods claimed. However, its narrow scope may limit its exclusionary reach across other similar compounds or methods.
4. What is the expiration date of RE48898?
Assuming standard term calculations and no extensions, expiration is around 2039, subject to maintenance payments and potential adjustments.
5. Are there ongoing patent filings that expand the scope of this patent?
Related applications exist internationally, but no recent filings appear to significantly extend or broaden the scope beyond the original claims.
References
[1] USPTO Patent RE48898, "Method of Treating or Preventing Cancer," issued 2019.
